These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 25087702)
1. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Oya K; Kishi T; Iwata N Hum Psychopharmacol; 2014 Sep; 29(5):483-91. PubMed ID: 25087702 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Kishi T; Iwata N CNS Drugs; 2013 Sep; 27(9):731-41. PubMed ID: 23812802 [TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. Solmi M; Veronese N; Thapa N; Facchini S; Stubbs B; Fornaro M; Carvalho AF; Correll CU CNS Spectr; 2017 Oct; 22(5):415-426. PubMed ID: 28181901 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials. Oya K; Matsuda Y; Matsunaga S; Kishi T; Iwata N Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):439-50. PubMed ID: 26303414 [TBL] [Abstract][Full Text] [Related]
5. Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials. Xiang YQ; Zheng W; Wang SB; Yang XH; Cai DB; Ng CH; Ungvari GS; Kelly DL; Xu WY; Xiang YT Eur Neuropsychopharmacol; 2017 Jan; 27(1):8-18. PubMed ID: 27919523 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of noradrenalin reuptake inhibitor augmentation therapy for schizophrenia: a meta-analysis of double-blind randomized placebo-controlled trials. Kishi T; Mukai T; Matsuda Y; Moriwaki M; Iwata N J Psychiatr Res; 2013 Nov; 47(11):1557-63. PubMed ID: 23899496 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Okuyama Y; Oya K; Matsunaga S; Kishi T; Iwata N Neuropsychiatr Dis Treat; 2016; 12():3221-3236. PubMed ID: 28008259 [TBL] [Abstract][Full Text] [Related]
8. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Kishi T; Mukai T; Matsuda Y; Iwata N Neuromolecular Med; 2014 Mar; 16(1):61-9. PubMed ID: 23896722 [TBL] [Abstract][Full Text] [Related]
9. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. Correll CU; Maayan L; Kane J; Hert MD; Cohen D J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Oya K; Kishi T; Iwata N Neuropsychiatr Dis Treat; 2015; 11():2299-307. PubMed ID: 26366084 [TBL] [Abstract][Full Text] [Related]
11. Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Zheng W; Cai DB; Zhang QE; He J; Zhong LY; Sim K; Ungvari GS; Ning YP; Xiang YT J Psychiatr Res; 2019 Jun; 113():27-33. PubMed ID: 30878789 [TBL] [Abstract][Full Text] [Related]
12. NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. Kishi T; Iwata N J Psychiatr Res; 2013 Sep; 47(9):1143-9. PubMed ID: 23692933 [TBL] [Abstract][Full Text] [Related]
13. Amantadine for Antipsychotic-Related Weight Gain: Meta-Analysis of Randomized Placebo-Controlled Trials. Zheng W; Wang S; Ungvari GS; Ng CH; Yang XH; Gu YH; Li M; Xiang YQ; Xiang YT J Clin Psychopharmacol; 2017 Jun; 37(3):341-346. PubMed ID: 28383359 [TBL] [Abstract][Full Text] [Related]
14. Adjunctive minocycline for major mental disorders: A systematic review. Zheng W; Zhu XM; Zhang QE; Cheng G; Cai DB; He J; Ng CH; Ungvari GS; Peng XJ; Ning YP; Xiang YT J Psychopharmacol; 2019 Oct; 33(10):1215-1226. PubMed ID: 31294649 [TBL] [Abstract][Full Text] [Related]
15. Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Zheng W; Zhu XM; Zhang QE; Yang XH; Cai DB; Li L; Li XB; Ng CH; Ungvari GS; Ning YP; Xiang YT Schizophr Res; 2019 Apr; 206():13-20. PubMed ID: 30573406 [TBL] [Abstract][Full Text] [Related]
16. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. Kishi T; Matsuda Y; Nakamura H; Iwata N J Psychiatr Res; 2013 Feb; 47(2):149-54. PubMed ID: 23131856 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. Zhao MJ; Qin B; Wang JB; Zhang YP; Zhao JT; Mao YG; Zhang XY; Zhang RL J Clin Psychopharmacol; 2018 Feb; 38(1):55-59. PubMed ID: 29257786 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Zheng W; Xiang YT; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Correll CU Acta Psychiatr Scand; 2016 Nov; 134(5):385-398. PubMed ID: 27585549 [TBL] [Abstract][Full Text] [Related]
19. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. Harvey RC; James AC; Shields GE CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655 [TBL] [Abstract][Full Text] [Related]
20. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Hirota T; Kishi T Schizophr Res; 2013 Sep; 149(1-3):88-95. PubMed ID: 23870805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]